Mesoblast Ltd has released a press release.
Ryoncil Pricing Set and Available This Quarter
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
In the deck
Earlier from Mesoblast
- Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
- Dr. Gregory George MD PhD Joins Mesoblast Board
- Ryoncil Commercial Launch Update and Product Pipeline
- Mesoblast raises new capital for ryoncil commercial launch
- Trading Halt
Later from Mesoblast
- Arcadium Lithium PLC to be removed from the S&P/ASX 200
- Mesoblast Added to S&P/ASX 200 INDEX
- Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
- Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
- Ryoncil® is Now Available for Purchase in the United States
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast